Indian Patents. 255258:"METHOD FOR PURIFICATION OR ISOLATION OF A PLASSMINOGEN OR A PROTEIN THAT IS A PLASMINOGEN ANALOGUE"

Title of Invention	"METHOD FOR PURIFICATION OR ISOLATION OF A PLASSMINOGEN OR A PROTEIN THAT IS A PLASMINOGEN ANALOGUE"
Abstract	The present invention provides a method for the purification and isolation of plasminogen or a protein that is a plasminogen analogue, comprising contacting a sample containing plasminogen or a protein that is a plasminogen analogue with an affinity adsorbent of formula II whereby plasminogen or a protein that is a plasminogen analogue present in the sample binds to the affinity adsorbent.

Full Text	Field of the Invention This invention relates to compounds and their use as affinity ligands. Background of the Invention Plasminogen (alternatively known as microplasmin, PLG or angiostatin) is a single chain 91 kDa glycoprotein zymogen, and is the precursor of the fibrinolytic enzyme plasmin. The native form of plasminogen is composed of 791 amino acids with glutamic acid located at the N-terminal portion (Glu-plasminogen). Plasminogen has five homologous regions known as kringles. These regions are specific for the complimentary kringles located on tPA, uPA and prothrombin. These kringles have one high affinity and four low affinity lysine binding sites that mediate the interactions of plasminogen with fibrin and alpha-2-antiplasmin. Plasminogen is converted to plasmin via a cascade of various reactions that result in the hydrolysis of the Arg560-Val561 peptide bond of plasminogen, resulting in two chains which remain covalently associated by a disulfide bond. The main role of the trypsin-like protease plasmin is the breakdown of clots. Plasminogen deficiencies resulting from homo- or heterozygous mutations in the coding DNA manifest themselves in a number of pathologies, including ligneous conjunctivitis and thrombosis. Plasminogen is present in human plasma at a concentration of -100 µg/mL It is possible to purify the plasminogen from plasma using immobilised lysine on a solid support, in an affinity chromatography process that is well characterised. Immobilised lysine chromatography is also used for the primary capture from cell culture harvest of proteins such as tissue plasminogen activator (tPA), commonly used as a clot-busting drug. The binding capacities of commercially available resins for plasminogen are typically in the range 0.6-1.0 mg protein/mL of adsorbent. The purity of the plasminogen eluted from these materials is excellent, with purity routinely > 95% from primary capture. It would be useful to have a material retaining these characteristics of excellent elution purity, but displaying a binding capacity in excess of those currently available. WO97/10887 discloses triazine-based compounds, useful as affinity adsorbents, of formula I (Formula Removed) wherein R1 is H, alkyl, hydroxyalkyl, cyclohexyl, NH2, phenyl, naphthyl, 1-phenylpyrazole, indazole, benzthiazole, benzoxazole or benzimidazoie, any of which aromatic groups can be substituted with one or more of alkyl, lalkoxy, acyloxy, acylamino, amino, NH2, OH, CO2H, sulphonyl, carbamoyl, sulphamoyl, alkylsulphonyl and halogen; one X is N and the other is N, C-CI or C-CN; Y is O,S or NR2; Z is O, S or NR3; R2 and R3 are each H, alkyl, hydroxyalkyl, benzyl or ß-phenylethyl; Q is benzene, naphthalene, benzthiazole, benzoxazole, 1-phenylpyrazole, indazole or benzimidazoie; R4, R5 and R6 are each H, OH, alkyl, alkoxy, amino, NH2, acyloxy, acylamino, CO2H, sulphohic acid, carbamoyl, sulphamoyl, alkylsulphonyl or halogen; n is 0 to 6; p is 0 to 20; and A is a support matrix/optionally linked to the triazine ring by a spacer. Compounds of formula I are disclosed as having affinity for proteins such as immunoglobulins, insulin, Factor VII or human growth hormone. Compounds of related structure are disclosed in WO00/67900 and WO03/097112. They have affinity for endotoxins. Summary of the Invention Surprisingly, it has been found that certain compounds, many of which are novel, are useful for affinity-based isolation of plasminogen. These compounds are of formula II (Formula Removed) wherein A, X and Z are as defined for formula I above; B is an optionally substituted hydrocarbon linkage containing from 1 to 10 carbon atoms; D is H, OH or a primary amino, secondary amino, tertiary amino, quaternary ammonium, imidazole, guanidino or amidino group; or B-D is-CHCOOH-(CH2)3-4-NH2; and q is 2 to 6. Further, compounds of the invention include the corresponding ligands, in which A is replaced by a functional group, linked directly or indirectly to the triazine ring, which can be reacted so that the compound is immobilised on a support matrix. The terms "ligand" and "adsorbent" may be used interchangeably, below. Description of the Invention WO97/10887, WO00/67900 and WO03/097112 disclose how combinatorial libraries of ligands can be built on a solid support. Their disclosures, including examples of embodiments and procedures common to the present invention, are incorporated herein by reference. During the screening of a set of these combinatorial libraries with pooled human plasma as feedstock, a number of ligands were identified as being capable of selectively binding and. eluting human plasminogen. Compounds of formula II, for use in the invention, can be prepared by procedures.known to those skilled in the art. Such procedures are described in the 3 PCT publications identified above; they can be readily adapted to the preparation of new compounds. In compounds of the invention, q is preferably 4. It will be appreciated that this "arm" of the molecule is derived from lysine. B preferably includes an aromatic, e.g. benzene, ring. WO97/10887 gives examples of A, including spacers or linkers L via which the triazine ring may be linked to a solid support M. As described in WO97/10887, such supports include agarose, silica, cellulose, dextran, starch, alginate, carrageenan, synthetic polymers, glass and metal oxides. Such materials may be activated before reaction to form an adsorbent of this invention. L may be, for example, -T-(-V1-V2)m-, wherein T is O, S or -NR7-; m is 0 or 1; V1 is an optionally substituted hydrocarbon radical of 2 to 20 C atoms; and V2 is O, S, -COO-, -CONH-, -NHCO-, -PO3H-, -NH-arylene-SO2-CH2-CH2- or -NR8-;and R7 and R8 are each independently H or C1-6 alkyl. In a preferred embodiment of the invention, the plasminogen-binding adsorbent is represented by structure III (Structure Removed) In a further preferred embodiment of the invention, the plasminogen-binding adsorbent is represented by structure IV (Structure Removed) In a further preferred embodiment of the invention, the plasminogen-binding adsorbent is represented by structure V (Structure Removed) The plasminogen-binding ligands and adsorbents described herein are useful for the affinity isolation and purification of plasminogen from various fluids and. complex mixtures including, but not limited to, human plasma, human plasma depleted of one or more other proteins and recombinant fermentation supernatants. This utility is demonstrated below in Example 4, by chromatography experiments using human pooled plasma. The term "plasminogen" is used herein to describe plasminogen itself and also analogues that have the functional characteristics of plasminogen, e.g. in terms of affinity to a given compound described herein. Thus, the analyte may be a protein that is a functional fragment of plasminogen, or a structural analogue having one, more of all of the same binding sites, or a fusion protein. The following Examples illustrate the invention. Example 1 - Synthesis of Adsorbent III 6% cross-linked Purabead agarose gel (1000 g settled in Reverse Osmosis (RO) water) was slurried with RO water (670 mL), 10 M sodium hydroxide (NaOH) (90 mL), and epichlorohydrin (127 mL). The slurry was stirred over 2 hours. After a sample was taken for analysis, the slurry was filtered, then washed with RO water (12 x 1 L). Analysis for epoxy' groups showed that the gel was derivatised with 17.3 pmol epoxy groups per g of settled gel. The gel was drained before RO water (800 mL) and 0.88 specific gravity aqueous ammonia solution (200 mL) were added. The mixture was stirred and heated to 40°C, then stirred at this temperature over 16 hours. After a sample was taken for analysis, the slurry was filtered, then washed with RO water (12 x 1000 mL). TNBS analysis for amine groups showed that the gel was derivatised with 25.6 umol amine groups per g of settled gel. The settled, aminated gel (1000 g) was suspended in 1 M potassium phosphate pH 7.0 (1 L), then allowed to drain. To this gel was then added 1 M potassium phosphate pH 7.0 (250 mL), and RO water (250 mL). The slurry was stirred vigorously while acetone (500 mL) was added. After cooling in an ice/salt bath over 30 minutes, cyanuric chloride (25 g) in cold acetone (250 mL) was added in one portion. The mixture was stirred at 0°C over 1 hour, before being washed with 50% aqueous acetone (5x1 L), RO water (5x1 L), 50% aqueous acetone (5 x 1. L), and RO water (10 x 1 L). The gel was allowed to settle under gravity, before a sample was taken for analysis. Analysis for chloride release indicated that the gel was derivatised with 16.8 umol substituted dichlorotriazine per g of settled gel. Settled gel from the previous stage (1000 g) was slurried with 1 M potassium phosphate buffer (1 L) containing lysine hydrochloride (45 g), pH 8.5, at room temperature over 16 hours. The slurry was filtered, then washed with RO water (15 x 1 L). To 950 g (settled) of the gel slurried in RO water (950 mL) was added ethanolamine (14.82 g). The mixture was stirred at 60°C overnight. After a sample of the supernatant was taken for analysis, the slurry was filtered, then washed with RO water (12x1 L). Analysis for chloride release indicated that the gel had been derivatised with 22.7 umol ethanolamine per g of settled gel. The gel was Incubated in a final concentration of 0.5 M NaOH overnight at 40°C, then washed with 0.5 M NaOH (5x1 L). After the final wash was allowed to drain under gravity, 0.5 M NaOH (1 L) was added and the mixture incubated at 40°C overnight. The gel was then washed with 0.5 M NaOH (5x1 L), then RO water (10 x 1 L). After washing with 0.1 M PBS pH 7.0 Dichlorotriazine-activated agarose was prepared according to the method described in Example 1. Settled gel (41.5 g, 22 umol DCT/g settled) was reacted overnight at 60°C with an aqueous solution of lysine hydrochloride (1.67 g, 10 molar equivalents) in water (40 mL) while maintaining the pH at 9.0 with 10 M NaOH. At this point the gel was washed with 50% aqueous dimethyl formamide RO water (5 x 80 mL), 0.1 M HCI (5 x 80 mL), 30% isopropanol/0.2 M NaOH (5 x 80 mL), and RO water (5 x 80 mL), before storage in the cold room at 4°C in 20% v/v aqueous ethanoi. Example 3 - Synthesis of Adsorbent V Dichlorotriazine-activated agarose was prepared according to the method described in Example 1. Settled gel (43g, 21.1 µmol DCT/g settled) was reacted for 30 minutes at 5°C with a solution of 2-(hydroxymethyl)aniline (0.56 g, 5 molar equivalents) in 50% DMF/water (40 mL). At this point the gel was washed with 50% aqueous dimethyl formamide (5 x 80 mL), and RO water (5 x 80 mL). The gel was then reacted overnight at 60°C with an aqueous solution of lysine hydrochloride (1.71 g, 10 molar equivalents) in water (40 mL) while maintaining the pH at 9.6 with 10 M NaOH. At this point the gel was washed with 50% aqueous dimethyl formamide (5 x 80 mL), RO water (5 x 80 mL), 0.1 M HCI (5 x 80 mL), 30% isopropanol/0.2 M NaOH (5 x 80 mL), and RO water (5 x 80 mL), before storage in the cold room at 4°C in 20% v/v aqueous ethanoi. Example 4 - Chromatography with Adsorbents III, IV and V using human plasma Chromatography experiments were performed using a 1.6 cm internal diameter, 10 cm bed height column chromatography column using an Akta Explorer chromatography system. The column was equilibrated with 140 mM sodium chloride/20 mM sodium citrate/20 mM Tris pH 7.5 at 100 cm/hr. Human plasma (Adjusted to 20 mM Tris/pH 7.5 filtered through 3,0.8,0.45, and 0.2 urn filters, 1.3 L) was then loaded at 50 cm/hr. Post-load wash was with with 140 mM sodium chloride/20 mM sodium citrate/20 mM Tris pH 7.5 at 50 cm/hr to baseline absorbance. The column was then eluted with 140 mM sodium chloride/20 mM sodium citrate/20 mM Tris/500 mM e-aminocaproic acid, pH 7.5 at 100 cm/hr, and regenerated with 0.5 M sodium hydroxide. Load, non-bound, and elution fractions were analysed by nephelometry to determine binding capacities. SDS PAGE was carried out to determine purity. . The purity of elution fractions from all of the adsorbents was > 85%. Dynamic binding capacities (at 10% breakthrough) are shown in Table 1. Table 1 (Table Removed) We Claim: 1. A method for the purification or isolation of a plasminogen or a protein that is a plasminogen analogue, comprising contacting a sample containing plasminogen or a protein that is a plasminogen analogue with an affinity adsorbent characterized in that said affinity adsorbent is of formula II wherein one X is N and the other is N, C-CI or C-CN; (Formula Removed) A is a support matrix, optionally linked to the triazine ring by a spacer such as herein described; Z is O, S or N-R and R is H, C1-6 alkyl, C1-6 hydroxyalkyl, benzyl or (3- phenylethyl; B is an optionally substituted hydrocarbon linkage containing from 1 to 10 carbon atoms; D is OH or NH2; and q is 2 to 6; whereby, plasminogen or a protein that is a plasminogen analogue present in the sample binds to the affinity adsorbent of formula II. 2. The method as claimed in claim 1 wherein said plasminogen is in a sample of plasma. 3. The method as claimed in claims 1 or 2 wherein said adsorbent is of formula III (Formula Removed) 4. The method as claimed in claims 1 or 2 wherein said adsorbent is of formula formula IV (Formula Removed) 5. The method as claimed in claims 1 or 2 wherein said adsorbent is of formula formula V (Formula Removed) 6. The method as claimed in any preceding claim wherein said affinity adsorbent is a compound of formula II wherein one X is N and the other X is N, C-CI or C-CN; A is a support matrix, optionally linked to the triazine ring by a spacer; Z is NH; B is a hydrocarbon linkage containing from 1 to 10 carbon atoms; D is OH; and q is 2 to 6 7. A compound which is a precursor of a compound of formual II as claimed in claim 6, wherein A is replaced by a functional group, linked directly or indirectly to the triazine ring, which allows immobilisation of the precursor on a solid support.

Full Text

Field of the Invention
This invention relates to compounds and their use as affinity ligands. Background of the Invention
Plasminogen (alternatively known as microplasmin, PLG or angiostatin) is a single chain 91 kDa glycoprotein zymogen, and is the precursor of the fibrinolytic enzyme plasmin. The native form of plasminogen is composed of 791 amino acids with glutamic acid located at the N-terminal portion (Glu-plasminogen). Plasminogen has five homologous regions known as kringles. These regions are specific for the complimentary kringles located on tPA, uPA and prothrombin. These kringles have one high affinity and four low affinity lysine binding sites that mediate the interactions of plasminogen with fibrin and alpha-2-antiplasmin.
Plasminogen is converted to plasmin via a cascade of various reactions that result in the hydrolysis of the Arg560-Val561 peptide bond of plasminogen, resulting in two chains which remain covalently associated by a disulfide bond. The main role of the trypsin-like protease plasmin is the breakdown of clots.
Plasminogen deficiencies resulting from homo- or heterozygous mutations in the coding DNA manifest themselves in a number of pathologies, including ligneous conjunctivitis and thrombosis.
Plasminogen is present in human plasma at a concentration of -100 µg/mL It is possible to purify the plasminogen from plasma using immobilised lysine on a solid support, in an affinity chromatography process that is well characterised. Immobilised lysine chromatography is also used for the primary capture from cell culture harvest of proteins such as tissue plasminogen activator (tPA), commonly used as a clot-busting drug. The binding capacities of commercially available resins for plasminogen are typically in the range 0.6-1.0 mg protein/mL of adsorbent. The purity of the plasminogen eluted from these materials is excellent, with purity routinely > 95% from primary capture. It would be useful to have a material retaining these characteristics of excellent elution purity, but displaying a binding capacity in excess of those currently available.
WO97/10887 discloses triazine-based compounds, useful as affinity adsorbents, of formula I
(Formula Removed)
wherein R1 is H, alkyl, hydroxyalkyl, cyclohexyl, NH2, phenyl, naphthyl, 1-phenylpyrazole, indazole, benzthiazole, benzoxazole or benzimidazoie, any of which aromatic groups can be substituted with one or more of alkyl, lalkoxy, acyloxy, acylamino, amino, NH2, OH, CO2H, sulphonyl, carbamoyl, sulphamoyl, alkylsulphonyl and halogen;
one X is N and the other is N, C-CI or C-CN;
Y is O,S or NR2;
Z is O, S or NR3;
R2 and R3 are each H, alkyl, hydroxyalkyl, benzyl or ß-phenylethyl;
Q is benzene, naphthalene, benzthiazole, benzoxazole, 1-phenylpyrazole, indazole or benzimidazoie;
R4, R5 and R6 are each H, OH, alkyl, alkoxy, amino, NH2, acyloxy, acylamino, CO2H, sulphohic acid, carbamoyl, sulphamoyl, alkylsulphonyl or halogen;
n is 0 to 6;
p is 0 to 20; and
A is a support matrix/optionally linked to the triazine ring by a spacer.
Compounds of formula I are disclosed as having affinity for proteins such as immunoglobulins, insulin, Factor VII or human growth hormone.
Compounds of related structure are disclosed in WO00/67900 and WO03/097112. They have affinity for endotoxins. Summary of the Invention
Surprisingly, it has been found that certain compounds, many of which are novel, are useful for affinity-based isolation of plasminogen. These compounds are of formula II
(Formula Removed)
wherein A, X and Z are as defined for formula I above;
B is an optionally substituted hydrocarbon linkage containing from 1 to 10 carbon atoms;
D is H, OH or a primary amino, secondary amino, tertiary amino, quaternary ammonium, imidazole, guanidino or amidino group; or
B-D is-CHCOOH-(CH2)3-4-NH2; and
q is 2 to 6.
Further, compounds of the invention include the corresponding ligands, in which A is replaced by a functional group, linked directly or indirectly to the triazine ring, which can be reacted so that the compound is immobilised on a support matrix. The terms "ligand" and "adsorbent" may be used interchangeably, below. Description of the Invention
WO97/10887, WO00/67900 and WO03/097112 disclose how combinatorial libraries of ligands can be built on a solid support. Their disclosures, including examples of embodiments and procedures common to the present invention, are incorporated herein by reference. During the screening of a set of these combinatorial libraries with pooled human plasma as feedstock, a number of ligands were identified as being capable of selectively binding and. eluting human plasminogen.
Compounds of formula II, for use in the invention, can be prepared by procedures.known to those skilled in the art. Such procedures are described in the 3 PCT publications identified above; they can be readily adapted to the preparation of new compounds.
In compounds of the invention, q is preferably 4. It will be appreciated that this "arm" of the molecule is derived from lysine. B preferably includes an aromatic, e.g. benzene, ring.
WO97/10887 gives examples of A, including spacers or linkers L via which the triazine ring may be linked to a solid support M. As described in WO97/10887, such supports include agarose, silica, cellulose, dextran, starch, alginate, carrageenan, synthetic polymers, glass and metal oxides. Such materials may be activated before reaction to form an adsorbent of this invention.
L may be, for example, -T-(-V1-V2)m-, wherein
T is O, S or -NR7-;
m is 0 or 1;
V1 is an optionally substituted hydrocarbon radical of 2 to 20 C atoms; and
V2 is O, S, -COO-, -CONH-, -NHCO-, -PO3H-, -NH-arylene-SO2-CH2-CH2- or -NR8-;and
R7 and R8 are each independently H or C1-6 alkyl.
In a preferred embodiment of the invention, the plasminogen-binding adsorbent is represented by structure III
(Structure Removed)
In a further preferred embodiment of the invention, the plasminogen-binding adsorbent is represented by structure IV
(Structure Removed)
In a further preferred embodiment of the invention, the plasminogen-binding adsorbent is represented by structure V
(Structure Removed)
The plasminogen-binding ligands and adsorbents described herein are useful for the affinity isolation and purification of plasminogen from various fluids and. complex mixtures including, but not limited to, human plasma, human plasma depleted of one or more other proteins and recombinant fermentation supernatants. This utility is demonstrated below in Example 4, by chromatography experiments using human pooled plasma.
The term "plasminogen" is used herein to describe plasminogen itself and also analogues that have the functional characteristics of plasminogen, e.g. in terms of affinity to a given compound described herein. Thus, the analyte may be a protein that is a functional fragment of plasminogen, or a structural analogue having one, more of all of the same binding sites, or a fusion protein.
The following Examples illustrate the invention. Example 1 - Synthesis of Adsorbent III
6% cross-linked Purabead agarose gel (1000 g settled in Reverse Osmosis (RO) water) was slurried with RO water (670 mL), 10 M sodium hydroxide (NaOH) (90 mL), and epichlorohydrin (127 mL). The slurry was stirred over 2 hours. After a sample was taken for analysis, the slurry was filtered, then washed with RO water (12 x 1 L). Analysis for epoxy' groups showed that the gel was derivatised with 17.3 pmol epoxy groups per g of settled gel.
The gel was drained before RO water (800 mL) and 0.88 specific gravity aqueous ammonia solution (200 mL) were added. The mixture was stirred and heated to 40°C, then stirred at this temperature over 16 hours. After a sample was taken for analysis, the slurry was filtered, then washed with RO water (12 x 1000 mL). TNBS analysis for amine groups showed that the gel was derivatised with 25.6 umol amine groups per g of settled gel.
The settled, aminated gel (1000 g) was suspended in 1 M potassium phosphate pH 7.0 (1 L), then allowed to drain. To this gel was then added 1 M potassium phosphate pH 7.0 (250 mL), and RO water (250 mL). The slurry was stirred vigorously while acetone (500 mL) was added. After cooling in an ice/salt bath over 30 minutes, cyanuric chloride (25 g) in cold acetone (250 mL) was added in one portion. The mixture was stirred at 0°C over 1 hour, before being washed with 50% aqueous acetone (5x1 L), RO water (5x1 L), 50% aqueous acetone (5 x 1. L), and RO water (10 x 1 L). The gel was allowed to settle under gravity, before a sample was taken for analysis. Analysis for chloride release indicated that the gel was derivatised with 16.8 umol substituted dichlorotriazine per g of settled gel.
Settled gel from the previous stage (1000 g) was slurried with 1 M potassium phosphate buffer (1 L) containing lysine hydrochloride (45 g), pH 8.5, at room temperature over 16 hours. The slurry was filtered, then washed with RO water (15 x 1 L). To 950 g (settled) of the gel slurried in RO water (950 mL) was added ethanolamine (14.82 g). The mixture was stirred at 60°C overnight. After a sample of the supernatant was taken for analysis, the slurry was filtered, then washed with RO water (12x1 L). Analysis for chloride release indicated that the gel had been derivatised with 22.7 umol ethanolamine per g of settled gel.
The gel was Incubated in a final concentration of 0.5 M NaOH overnight at 40°C, then washed with 0.5 M NaOH (5x1 L). After the final wash was allowed to drain under gravity, 0.5 M NaOH (1 L) was added and the mixture incubated at 40°C overnight. The gel was then washed with 0.5 M NaOH (5x1 L), then RO water (10 x 1 L). After washing with 0.1 M PBS pH 7.0 Dichlorotriazine-activated agarose was prepared according to the method described in Example 1. Settled gel (41.5 g, 22 umol DCT/g settled) was reacted overnight at 60°C with an aqueous solution of lysine hydrochloride (1.67 g, 10 molar equivalents) in water (40 mL) while maintaining the pH at 9.0 with 10 M NaOH. At this point the gel was washed with 50% aqueous dimethyl formamide RO water (5 x 80 mL), 0.1 M HCI (5 x 80 mL), 30% isopropanol/0.2 M NaOH (5 x 80 mL), and RO water (5 x 80 mL), before storage in the cold room at 4°C in 20% v/v aqueous ethanoi. Example 3 - Synthesis of Adsorbent V
Dichlorotriazine-activated agarose was prepared according to the method described in Example 1. Settled gel (43g, 21.1 µmol DCT/g settled) was reacted for 30 minutes at 5°C with a solution of 2-(hydroxymethyl)aniline (0.56 g, 5 molar equivalents) in 50% DMF/water (40 mL). At this point the gel was washed with 50% aqueous dimethyl formamide (5 x 80 mL), and RO water (5 x 80 mL). The gel was then reacted overnight at 60°C with an aqueous solution of lysine hydrochloride (1.71 g, 10 molar equivalents) in water (40 mL) while maintaining the pH at 9.6 with 10 M NaOH. At this point the gel was washed with 50% aqueous dimethyl formamide (5 x 80 mL), RO water (5 x 80 mL), 0.1 M HCI (5 x 80 mL), 30% isopropanol/0.2 M NaOH (5 x 80 mL), and RO water (5 x 80 mL), before storage in the cold room at 4°C in 20% v/v aqueous ethanoi.
Example 4 - Chromatography with Adsorbents III, IV and V using human plasma
Chromatography experiments were performed using a 1.6 cm internal diameter, 10 cm bed height column chromatography column using an Akta Explorer chromatography system. The column was equilibrated with 140 mM sodium chloride/20 mM sodium citrate/20 mM Tris pH 7.5 at 100 cm/hr. Human plasma (Adjusted to 20 mM Tris/pH 7.5 filtered through 3,0.8,0.45, and 0.2 urn filters, 1.3 L) was then loaded at 50 cm/hr. Post-load wash was with with 140 mM sodium chloride/20 mM sodium citrate/20 mM Tris pH 7.5 at 50 cm/hr to baseline absorbance. The column was then eluted with 140 mM sodium chloride/20 mM sodium citrate/20 mM Tris/500 mM e-aminocaproic acid, pH 7.5 at 100 cm/hr, and regenerated with 0.5 M sodium hydroxide. Load, non-bound, and elution fractions were analysed by nephelometry to determine binding capacities. SDS PAGE was carried out to determine purity. .
The purity of elution fractions from all of the adsorbents was > 85%. Dynamic binding capacities (at 10% breakthrough) are shown in Table 1.
Table 1
(Table Removed)

We Claim:
1. A method for the purification or isolation of a plasminogen or a protein that is
a plasminogen analogue, comprising contacting a sample containing plasminogen
or a protein that is a plasminogen analogue with an affinity adsorbent characterized
in that said affinity adsorbent is of formula II wherein one X is N and the other is N,
C-CI or C-CN;
(Formula Removed)
A is a support matrix, optionally linked to the triazine ring by a spacer such
as herein described;
Z is O, S or N-R and R is H, C1-6 alkyl, C1-6 hydroxyalkyl, benzyl or (3-
phenylethyl;
B is an optionally substituted hydrocarbon linkage containing from 1 to 10
carbon atoms;
D is OH or NH2; and
q is 2 to 6;
whereby, plasminogen or a protein that is a plasminogen analogue present in the sample binds to the affinity adsorbent of formula II.
2. The method as claimed in claim 1 wherein said plasminogen is in a sample
of plasma.
3. The method as claimed in claims 1 or 2 wherein said adsorbent is of formula
III
(Formula Removed)
4. The method as claimed in claims 1 or 2 wherein said adsorbent is of formula
formula IV
(Formula Removed)
5. The method as claimed in claims 1 or 2 wherein said adsorbent is of formula
formula V
(Formula Removed)
6. The method as claimed in any preceding claim wherein said affinity
adsorbent is a compound of formula II wherein one X is N and the other X is
N, C-CI or C-CN; A is a support matrix, optionally linked to the triazine ring
by a spacer;
Z is NH;
B is a hydrocarbon linkage containing from 1 to 10 carbon atoms;
D is OH; and
q is 2 to 6
7. A compound which is a precursor of a compound of formual II as claimed in
claim 6, wherein A is replaced by a functional group, linked directly or indirectly to the triazine ring, which allows immobilisation of the precursor on a solid support.

Documents:

8572-delnp-2007-1-Correspondence Others-(15-05-2012).pdf

8572-delnp-2007-1-Petition-137-(15-05-2012).pdf

8572-DELNP-2007-Abstract-(15-05-2012).pdf

8572-DELNP-2007-Abstract-(22-11-2011).pdf

8572-delnp-2007-abstract.pdf

8572-DELNP-2007-Claims-(15-05-2012).pdf

8572-DELNP-2007-Claims-(22-11-2011).pdf

8572-delnp-2007-claims.pdf

8572-delnp-2007-Correspondence Others-(09-07-2012).pdf

8572-DELNP-2007-Correspondence Others-(15-05-2012).pdf

8572-DELNP-2007-Correspondence Others-(22-11-2011).pdf

8572-DELNP-2007-Correspondence Others-(29-09-2011).pdf

8572-delnp-2007-correspondence-others (10-03-2008).pdf

8572-delnp-2007-correspondence-others.pdf

8572-DELNP-2007-Description (Complete)-(15-05-2012).pdf

8572-DELNP-2007-Description (Complete)-(22-11-2011).pdf

8572-delnp-2007-description (complete).pdf

8572-DELNP-2007-Form-1-(15-05-2012).pdf

8572-DELNP-2007-Form-1-(22-11-2011).pdf

8572-delnp-2007-form-1.pdf

8572-delnp-2007-form-18 (10-03-2008).pdf

8572-DELNP-2007-Form-2-(15-05-2012).pdf

8572-DELNP-2007-Form-2-(22-11-2011).pdf

8572-delnp-2007-form-2.pdf

8572-delnp-2007-Form-3-(09-07-2012).pdf

8572-DELNP-2007-Form-3-(15-05-2012).pdf

8572-DELNP-2007-Form-3-(29-09-2011).pdf

8572-delnp-2007-form-3.pdf

8572-delnp-2007-form-5.pdf

8572-delnp-2007-pct-101.pdf

8572-delnp-2007-pct-210.pdf

8572-delnp-2007-pct-304.pdf

8572-delnp-2007-pct-308.pdf

8572-delnp-2007-Petition-137-(09-07-2012).pdf

« Previous Patent

Next Patent »

Patent Number

255258

Indian Patent Application Number

8572/DELNP/2007

PG Journal Number

06/2013

Publication Date

08-Feb-2013

Grant Date

07-Feb-2013

Date of Filing

06-Nov-2007

Name of Patentee

PROMETIC BIOSCIENCES LTD.

Applicant Address

FREEEPORT, BALLASALLA, ISLE OF MAN IM9 2AP, U.K.

Inventors:

#	Inventor's Name	Inventor's Address
1	BETLEY, JASON, RICHARD	17 CHURCH STREET, BUNTINGFORD, HERTFORDSHIRE, SG 9 9AS, U.K.
2	BAINES, BALDEV, SINGH	PROMETIC BIOSCIENCES LTD., 211 CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE CB4 0ZA, U.K.
3	PEARSON, JAMES, CHRISTOPHER	PROMETIC BIOSCIENCES LTD., 211 CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE CB4 0ZA, U.K.
4	KUHN, CLAUDIA, HILDEGARD	PROMETIC BIOSCIENCES LTD., 211 CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE CB4 0ZA, U.K.

PCT International Classification Number

B01J 20/32

PCT International Application Number

PCT/GB2006/001686

PCT International Filing date

2006-05-09

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	0509438.8	2005-05-09	U.K.